Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lung Neoplasms Clear all
Completed Phase 2 Interventional

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

NCT04010357
View directory record Official record
Conditions
Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Interventions
Abemaciclib,
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

NCT00596830
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
169
States / cities
Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 22, 2026, 1:35 AM EDT
Recruiting Phase 2Phase 3 Interventional

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

NCT07226999
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
PF-08634404, Atezolizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
54
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

NCT03382899
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pegilodecakin, Pembrolizumab
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
74
States / cities
Huntsville, Alabama • Tempe, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NCT03127098
View directory record Official record
Conditions
Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
Interventions
ETBX-011, ALT-803
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 1 Interventional

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

NCT00003263
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
recombinant interferon alfa, cisplatin, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
3
States / cities
Marrero, Louisiana • Philadelphia, Pennsylvania • Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 2 Interventional Results available

PROactive Evaluation of Function to Avoid CardioToxicity

NCT03862131
View directory record Official record
Conditions
Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
Interventions
MyoStrain®
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

NCT02316002
View directory record Official record
Conditions
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Early Phase 1 Interventional

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT01781741
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment
Combination Product · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 22, 2026, 1:35 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872
View directory record Official record
Conditions
Small Cell Lung Carcinoma Extensive Disease
Interventions
Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Recruiting Phase 2 Interventional

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

NCT07207395
View directory record Official record
Conditions
Lung Cancer (NSCLC)
Interventions
JBI-802, Pembrolizumab
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated No phase listed Observational

Afatinib Genomic Landscape

NCT02491775
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-small Lung Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 1 Interventional

Study of Continuous OSI-906 Dosing

NCT00514007
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Testing the Feasibility of a Simplified Workflow for Lung Cancer

NCT04844736
View directory record Official record
Conditions
Lung Cancer
Interventions
CT Simulation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
High Point, North Carolina • Lexington, North Carolina • Statesville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

NCT00003111
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, irinotecan hydrochloride, paclitaxel, neoadjuvant therapy, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 22, 2026, 1:35 AM EDT
Completed No phase listed Observational Results available

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

NCT03833934
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Not applicable Interventional

Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy

NCT02011087
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
bioelectric impedance analysis
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

NCT00563784
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer
Interventions
Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)

NCT05021133
View directory record Official record
Conditions
Lung Cancer
Interventions
Tele-Navi LCS
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
50 Years to 77 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Multidisciplinary Inpatient Palliative Care Intervention

NCT00325611
View directory record Official record
Conditions
Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions
Multidisciplinary palliative care team met with patient
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 22, 2026, 1:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

NCT03168464
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Ipilimumab, Nivolumab, Radiation therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Early Phase 1 Interventional

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

NCT05873439
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Interventions
Genomically Guided Radiation Therapy (RT)
Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 1:35 AM EDT
No Longer Available No phase listed Expanded access

Rociletinib (CO-1686) USA Expanded Access Program

NCT02547675
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
Scottsdale, Arizona • Fountain Valley, California • Monterey, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 22, 2026, 1:35 AM EDT
Completed Phase 1 Interventional

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 22, 2026, 1:35 AM EDT